The combination of daily oral administration of CDK4/6 inhibitors (Abemaciclib or Palbociclib) and intraperitoneal anti-PD-1 treatment markedly suppressed tumor growth, compared with anti-PD-1 or CDK4/6 inhibitor alone. Here, CDK4 is linked to neoplasm.